LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030 Report

Global LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030 Report Findings & Highlights:

Global LAG-3 Targeting Therapies Market Opportunity By 2030: > USD 4 Billion
Global & Regional Market Insight
Approved Drug Global & Regional Sales Analysis
Approved LAG-3 Drug Dosing, Pricing & Sales Insight
Global LAG3 Inhibitors clinical Trials Insight By Company, Country, Indication and Phase
Insight On More Than 35 LAG-3 Targeted Therapies In Clinical Trials
Expected Completion Time For Key Drugs In Clinical Trials

The potential of LAG-3 targeting therapy to treat a number of ailments, particularly cancer, autoimmune diseases, and inflammatory diseases, has attracted a lot of attention to the global market. An immune checkpoint receptor called lymphocyte-activation gene 3 (LAG-3) is essential for controlling immune responses. As a result, a number of treatments have been developed to modify LAG-3 activity, either by activation, depletion, or inhibition, each with unique therapeutic uses. The most popular strategy among them is LAG-3 inhibition, but LAG-3 activation and depletion, both of which were developed by Immutep, are also becoming more popular.

In this market, LAG-3 inhibition is still the most popular therapeutic strategy because it aims to improve the immune system's capacity to recognize and eliminate cancer cells. The approach primarily involves the use of monoclonal antibodies, which are intended to inhibit the LAG-3 receptor, effectively maximizing T-cells to attack tumor cells. Bispecific antibodies, such as ZGGS-15, which targets both TIGIT and LAG-3, represent an upcoming and innovative class of therapies. Suzhou Zelgen Biopharmaceuticals' ZGGS-15 is specifically designed to treat solid tumors. Bispecific antibodies have the potential to increase the effectiveness of immune therapies by simultaneously targeting two immune checkpoint pathways, particularly for complex conditions like solid tumors that are typically more difficult to treat.

In addition to cancer, researchers are also looking into how LAG-3 targeting might be used to treat autoimmune and inflammatory disorders. Although research in this area is still in its early stages, there is also mounting evidence that suggests LAG-3 modulation may have therapeutic benefits in microbial diseases. The main focus, however, is still on cancer treatment, especially in the context of immunotherapy, where LAG-3 inhibition is thought to be a means of overcoming immune suppression brought on by tumors.

The drug Opdualag, which combines the anti-PD-1 monoclonal antibody nivolumab with the anti-LAG-3 monoclonal antibody relatlimab, is a significant success story in this field. Approved in 2022, Opdualag's revenue surpassed US$ 250 million that year, and in 2024, it exceeded US$ 900 million. This remarkable expansion indicates a promising future for similar treatments and reflects the growing acceptance of LAG-3 targeting therapies in the oncology market.

More than 35 LAG-3 targeting candidates are presently undergoing clinical development, demonstrating the expansive interest and continuous innovation in this area. Regeneron Pharmaceuticals is a major player in this market thanks to Fianlimab, one of its lead candidates. Fianlimab, which is presently undergoing Phase 3 trials, is being evaluated for a number of cancer indications and could have considerable effects on the treatment environment. Immutep's IMP-761, a first-in-class LAG-3 agonist, is another exciting candidate. IMP-761 is being tested for safety and effectiveness in humans in early phase trials, after which, the treatment will be expanded to autoimmune disorders.

Thus, the increasing number of clinical trials and the expanding therapeutic indications for LAG-3 targeting therapies indicate this market is positioned for substantial growth in the coming years. The amalgamation of monoclonal and bispecific antibodies, along with the ongoing pursuit of LAG-3 agonism and depletion, presents a wide array of potential treatments that could revolutionize the management of cancer, autoimmune diseases, and beyond. LAG-3 targeted therapies are anticipated to become increasingly essential in immuno-oncology and other immune-related disorders as research advances, propelling additional market growth.

1. Introduction to LAG-3 Targeting Therapies

1.1 LAG-3 As Therapeutic Target
1.2 LAG-3 Targeting Therapies - Mechanism Of Action
1.3 LAG-3 Targeting Approaches

2. Combination Strategies For LAG-3 Targeting Therapies

3. Global LAG-3 Targeting Therapy Market Scenario

3.1 Current Market Outlook
3.2 Future Market Outlook

4. LAG-3 Targeting Therapy Market Regional Analysis

4.1 US
4.2 EU
4.3 China
4.4 Australia
4.5 UK
4.6 Japan
4.7 Canada
4.8 South Korea

5. LAG-3 Targeting Therapy - Development Trends By Indication

5.1 Cancer
5.1.1 Lymphoma
5.1.2 Melanoma
5.1.3 Lung Cancer
5.1.4 Gastrointestinal Cancers
5.1.5 Head & Neck Cancer
5.2 Autoimmune & Inflammatory Diseases
5.3 Microbial Infections

6. Opdualag (Nivolumab & Relatlimab) - Overview, Pricing, Dosing & Sales Analysis

6.1 Overview & Patent Insight
6.2 Pricing & Dosing
6.3 Sales Insight

7. Global LAG-3 Targeting Therapies Clinical Trials Overview

7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
7.6 Patient Segment

8. Global LAG3 Targeting Therapies clinical Trials Insight By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III

9. Marketed LAG-3 Inhibitor Clinical Insight

10. Global LAG-3 Targeting Therapy Market Dynamics

10.1 Market Drivers
10.2 Market Challenges

11. Competitive Landscape

11.1 ABL Bio
11.2 Agenus
11.3 Akeso Biopharma
11.4 Bristol-Myers Squibb
11.5 EpimAb Biotherapeutics
11.6 F-star Therapeutics
11.7 Immutep
11.8 Innovent Biologics
11.9 Shanghai Henlius Biotech
11.10 Y-Biologics

List of Tables and Figures

Figure 1-1: LAG-3/MHC Class II Signaling Pathway
Figure 1-2: LAG-3 Targeted Therapy Landscape - Milestones
Figure 1-3: LAG-3 Inhibitor - Mechanism Of Action
Figure 1-4: LAG-3 Agonist - Mechanism Of Action
Figure 1-5: LAG-3 Depletion - Mechanism Of Action
Figure 1-6: Bispecific Antibodies - Binding Efficacy
Figure 2-1: Overview to LAG-3 Combinations
Figure 3-1: Global - LAG 3 Targeting Therapy Market Value (US$ Million), 2022-2024
Figure 3-2: Global - LAG 3 Targeting Therapy Market Value By Region (US$ Million), 2024
Figure 3-3: Global - LAG 3 Targeting Therapy Market Value By Region (%), 2024
Figure 3-4: Global - Quarterly LAG 3 Targeting Therapy Market Value (US$ Million), 2024
Figure 3-5: Global - LAG 3 Targeting Therapy Market Forecast (US$ Million), 2025 - 2030
Figure 3-6: Global LAG-3 Targeting Therapy Market - Future Outlook
Figure 4-1: EU - Research Institutes & Hospitals Conducting LAG-3 Therapy Clinical Trials
Figure 5-1: RELATIVITY-069 Phase 1/2 (NCT05255601) Study - Initiation & Completion Year
Figure 5-2: AK129-102 Phase 1/2 (NCT06642792) Study - Initiation & Completion Year
Figure 5-3: R3767-ONC-2011 Phase 3 (NCT05352672) Study - Initiation & Completion Year
Figure 5-4: R3767-ONC-2055 Phase 3 (NCT05352672) Study - Initiation & Completion Year
Figure 5-5: INCAGN 2385-201 Phase 1/2 (NCT04370704) Study - Initiation & Completion Year
Figure 5-6: R3767-ONC-2235 Phase 2/3 (NCT05785767) Study - Initiation & Completion Year
Figure 5-7: R3767-ONC-2236 Phase 2/3 (NCT05800015) Study - Initiation & Completion Year
Figure 5-8: R2810-ONC-1866 Phase 2 (NCT03916627) Study - Initiation & Completion Year
Figure 5-9: R2810-ONC-2266 Phase 2 (NCT06161441) Study - Initiation & Completion Year
Figure 5-10: RELATIVITY-104 Phase 2 (NCT04623775) Study - Initiation & Completion Year
Figure 5-11: RELATIVITY-1093 Phase 3 (NCT06561386) Study - Initiation & Completion Year
Figure 5-12: J23155 Phase 2 (NCT06205836) Study - Initiation & Completion Year
Figure 5-13: J1714 Phase 1b (NCT03044613) Study - Initiation & Completion Year
Figure 5-14: RELATIVITY-123 Phase 3 (NCT05328908) Study - Initiation & Completion Year
Figure 5-15: NP41300 Phase 1/2 (NCT04140500) Study - Initiation & Completion Year
Figure 5-16: LBL-007-CN-003 Phase 1b/2 (NCT05102006) Study - Initiation & Completion Year
Figure 5-17: HCC 18-139 Phase 2 (NCT04080804) Study - Initiation & Completion Year
Figure 5-18: IMP761-P001 Phase 1 (NCT06637865) Study - Initiation & Completion Year
Figure 6-1: Opdualag - Approval Year by Region
Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Year By Region
Figure 6-3: US - Cost Per Unit & Supply Of Opdualag (US$), April’2025
Figure 6-4: Cost Per Unit & Supply Of Opdualag (US$), April’2025
Figure 6-5: Global - Opdualag Annual Sales (US$ Million), 2022-2024
Figure 6-6: Global - Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 6-7: Opdualag - US v/s ROW Sales (US$ Million), 2024
Figure 6-8: Global - Opdualag Sales (US$ Million), 2024
Figure 6-9: US - Opdualag Sales (US$ Million), 2022-2024
Figure 6-10: US - Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 6-11: ROW - Opdualag Sales (US$ Million), 2022-2024
Figure 6-12: ROW - Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 7-1: Global - LAG-3 Inhibitor Clinical Trials By Phase (Numbers), 2025 - 2030
Figure 7-2: Global - LAG-3 Inhibitor Clinical Trials By Country (Numbers), 2025 - 2030
Figure 7-3: Global - LAG-3 Inhibitor Clinical Trials By Company (Numbers), 2025 - 2030
Figure 7-4: Global - LAG-3 Inhibitor Clinical Trials By Indication (Numbers), 2025 - 2030
Figure 7-5: Global - LAG-3 Inhibitor Clinical Trials By Priority Status (Numbers), 2025 - 2030
Figure 7-6: Global - LAG-3 Inhibitor Clinical Trials By Patient Segment (Numbers), 2025 - 2030
Figure 10-1: Global LAG-3 Targeting Therapy Market - Drivers & Opportunities
Figure 10-2: Global LAG-3 Targeting Therapy Market - Challenges & Restraints
Table 2-1: Ongoing Preclinical & Clinical Trials For Combination of LAG-3 inhibitors, April’2025
Table 4-1: US - Ongoing Clinical Trials For LAG-3 Targeting Therapies, April’2025
Table 4-2: China - Ongoing Clinical Trials For LAG-3 Targeting Therapies, April’2025
Table 4-3: Immutep - Active Patents By Region
Table 5-1: Melanoma - Some Ongoing Clinical Trials For LAG-3 Inhibitors, April’2025
Table 6-1: Opdualag - Maximum Infusion Volumes & Concentration Ranges By Patient Group 1
Table 6-2: Opdualag - Recommended Dosage Modifications For Adverse Reactions

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

ABL Bio
Agenus
Akeso Biopharma
Bristol-Myers Squibb
EpimAb Biotherapeutics
F-star Therapeutics
Immutep
Innovent Biologics
Shanghai Henlius Biotech
Y-Biologics

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2018EUR$2,160USD£1,707GBP €2242EUR$2,400USD£1,897GBP
Hard Copy	A printed copy of the product will be shipped to you.		€3643EUR$3,900USD£3,082GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4092EUR$4,380USD£3,462GBP €4484EUR$4,800USD£3,794GBP

Global LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030 Report Findings & Highlights:

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Reports

Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028

Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030

Crohn's Disease (Regional Enteritis) - Global Clinical Trials Review, 2024

Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024 - 2030

Immuno-oncology Clinical Trials Market by Design, Phase, Indication - Global Forecast 2025-2030